It is worth mentioning that Innovent's pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference's total oral presentations. PD-1/IL-2 ...

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a ...

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...

* Note: one patient in 0.6/1/1.5mg/kg group finished treatment without at least one post-baseline tumor assessment. Higher ORR and PFS were observed in lung adenocarcinoma patients with a history of ...

Dr. Hui Zhou, Senior Vice President of Innovent, said, "We are pleased to present an oral update on IBI343's clinical data at this year's ASCO conference. With the unique Fc-silent antibody design, ...

BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound ...

What it means: AI can take over repetitive or administrative tasks–such as drafting rubrics, generating assessments, and writing newsletters–giving teachers more capacity to lead instructionally. Why ...

2. Reducing teacher burden What it means: AI can take over repetitive or administrative tasks–such as drafting rubrics, generating assessments, and writing newsletters–giving teachers more capacity to ...

YANTAI, China I June 2, 2025 I On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical ...

It is worth mentioning that Innovent’s pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference’s total oral presentations. Innovent ...

"We are pleased to present an oral update on IBI343's clinical data at this year's ASCO conference. With the unique Fc-silent antibody design, stable linker and potent TOPO1i payload, IBI343 is the ...

The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 30 days. Tafasitamab (Monjuvi ...